CHMP gives green light to Recordati's BPH drug
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended approval for Recordati's Silodyx (silodosin; also known as Urorec) for signs and symptoms of benign prostatic hyperplasia (BPH). The drug is already available in several markets including Japan, where it is marketed by drug originator Kissei as Urief, and in the US, where it is marketed by Watson as Rapaflo.